Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Forman

Showing results (301-310 of 503) with videos related to

Pageof 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study ReportAndrew M McDonald, Yanjun Chen, Jessica Wu, et al.
Journal of Cellular Physiology|January 10, 2019
The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AMLLe Xuan Truong Nguyen, Estelle Troadec, Arjun Kalvala, et al.
Blood|February 11, 2005
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor StudySmita Bhatia, Leslie L Robison, Liton Francisco, et al.
Leukemia & Lymphoma|October 17, 2019
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignanciesTanya Siddiqi, Paul Frankel, Jan H Beumer, et al.
Cancer|November 22, 2022
Potentially inappropriate medications in geriatric blood or marrow transplantation (BMT) survivors: A BMT Survivor Study reportSebastian Sanchez-Luege, Wendy Landier, Chen Dai, et al.
Blood|May 27, 2014
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patientsArthur E Frankel, Jung H Woo, Chul Ahn, et al.
Cancer|October 9, 2024
Self-rated health is an independent predictor of subsequent late mortality after blood or marrow transplantation: A Blood or Marrow Transplant Survivor Study reportNora Balas, Joshua Richman, Wendy Landier, et al.
Blood Advances|September 8, 2023
Risky health behaviors and subsequent late mortality after blood or marrow transplantation: a BMTSS reportNora Balas, Joshua Richman, Wendy Landier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 1, 2020
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous LeukemiaKaramjeet S Sandhu, Sanjeet Dadwal, Dongyun Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemiaVivian G Oehler, Jerald P Radich, Barry Storer, et al.
Pageof 51

Showing results (301-310 of 503) with videos related to

Sort By:
Pageof 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study ReportAndrew M McDonald, Yanjun Chen, Jessica Wu, et al.
Journal of Cellular Physiology|January 10, 2019
The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AMLLe Xuan Truong Nguyen, Estelle Troadec, Arjun Kalvala, et al.
Blood|February 11, 2005
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor StudySmita Bhatia, Leslie L Robison, Liton Francisco, et al.
Leukemia & Lymphoma|October 17, 2019
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignanciesTanya Siddiqi, Paul Frankel, Jan H Beumer, et al.
Cancer|November 22, 2022
Potentially inappropriate medications in geriatric blood or marrow transplantation (BMT) survivors: A BMT Survivor Study reportSebastian Sanchez-Luege, Wendy Landier, Chen Dai, et al.
Blood|May 27, 2014
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patientsArthur E Frankel, Jung H Woo, Chul Ahn, et al.
Cancer|October 9, 2024
Self-rated health is an independent predictor of subsequent late mortality after blood or marrow transplantation: A Blood or Marrow Transplant Survivor Study reportNora Balas, Joshua Richman, Wendy Landier, et al.
Blood Advances|September 8, 2023
Risky health behaviors and subsequent late mortality after blood or marrow transplantation: a BMTSS reportNora Balas, Joshua Richman, Wendy Landier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 1, 2020
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous LeukemiaKaramjeet S Sandhu, Sanjeet Dadwal, Dongyun Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemiaVivian G Oehler, Jerald P Radich, Barry Storer, et al.
Pageof 51